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Abstract
Introduction: There are limited data on paediatric HIV care and treatment programmes in low-resource settings.
Methods: A standardized survey was completed by International epidemiologic Databases to Evaluate AIDS paediatric cohort
sites in the regions of Asia-Pacific (AP), Central Africa (CA), East Africa (EA), Southern Africa (SA) and West Africa (WA) to
understand operational resource availability and paediatric management practices. Data were collected through January 2010
using a secure, web-based software program (REDCap).
Results: A total of 64,552 children were under care at 63 clinics (AP, N10; CA, N4; EA, N29; SA, N10; WA, N10).
Most were in urban settings (N41, 65%) and received funding from governments (N51, 81%), PEPFAR (N34, 54%), and/or
the Global Fund (N15, 24%). The majority were combined adultpaediatric clinics (N36, 57%). Prevention of mother-
to-child transmission was integrated at 35 (56%) sites; 89% (N56) had access to DNA PCR for infant diagnosis. African (N40/
53) but not Asian sites recommended exclusive breastfeeding up until 46 months. Regular laboratory monitoring included CD4
(N60, 95%), and viral load (N24, 38%). Although 42 (67%) sites had the ability to conduct acid-fast bacilli (AFB) smears,
23 (37%) sites could conduct AFB cultures and 18 (29%) sites could conduct tuberculosis drug susceptibility testing. Loss to
follow-up was defined as 3 months of lost contact for 25 (40%) sites, 6 months for 27 sites (43%) and 12 months for
6 sites (10%). Telephone calls (N52, 83%) and outreach worker home visits to trace children lost to follow-up (N45, 71%)
were common.
Conclusions: In general, there was a high level of patient and laboratory monitoring within this multiregional paediatric cohort
consortium that will facilitate detailed observational research studies. Practices will continue to be monitored as the WHO/
UNAIDS Treatment 2.0 framework is implemented.
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Introduction
UNAIDS estimates that 3.4 million children under the age of
15 years are currently living with HIV infection; 91% of these
children reside in sub-Saharan Africa [1]. HIV infection in
children progresses rapidly without treatment  over half of
the HIV-infected children in Africa die by the age of two years
if they do not receive antiretroviral therapy (ART) [2]. Highly
active antiretroviral therapy (HAART) results in marked
survival benefits for HIV-infected children [3]. However, at
the end of 2011, only 28% of the 2 million children in need of
treatment were receiving it, compared to 57% in adults; in
many countries, the disparity between paediatric and adult
access to treatment is even greater [14]. There are multiple
bottlenecks that limit paediatric treatment, including poor
access to early HIV diagnosis in infants, lack of health care
centres and providers equipped to deliver paediatric treat-
ment, limited availability of paediatric drug formulations and
the high cost of such formulations, the complexity of adjusting
dosing as a child ages and weak systems for patient retention.
To date, data are limited with regards to the structure and
outcomes of paediatric HIV care and treatment programmes
in resource-constrained settings. Understanding the avail-
ability of clinical management resources as well as the
application of prevention, diagnosis and treatment standards
is necessary to provide a context for observational cohort
studies. In turn, such studies are necessary to optimize
programme development, and to improve patient access and
outcomes. While information about local or national pro-
grammes may be available, the indicators used are not
necessarily comparable between countries or across regions
[57]. Large data gaps on the numbers of children living with
HIV and those who meet criteria for treatment initiation [8]
make it even more difficult to project the level of additional
resources needed to deliver paediatric HIV care.
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The International epidemiologic Databases to Evaluate
AIDS (IeDEA; www.iedea.org) is a global network that
includes paediatric cohorts located in Asia; the Caribbean
and South America; and Central, East, Southern, and West
Africa [9,10]. IeDEA provide a unique platform to evaluate
the health systems that support prevention, care and
treatment in some of the most experienced paediatric HIV
cohorts in these regions [11,12]. A global survey was
conducted in 2010 to determine and compare the resources




Regional investigators developed and standardized a site
assessment tool that included questions regarding site re-
sources, clinical practices and access to drugs and laboratory
monitoring for adult, paediatric and combined adult
paediatric clinical settings. Sites that had either paediatric-
only or combined paediatricadult programmes were asked
to respond to 253 questions regarding general programme
resources and clinical management (N110), general cancer
diagnostics and management (N44), paediatric-specific
information (N61) and paediatric cancer diagnostics and
management (N38). Multi-lingual versions of the site
assessment tool were implemented using the REDCap
(Research Electronic Data Capture) system, a secure, web-
based application designed to support data capture for
research studies (project-redcap.org). REDCap was developed
at the Vanderbilt Institute for Clinical and Translational
Research. It provides an interface for validated data entry,
audit trails for tracking data manipulation and automated
import and export procedures to common statistical packages
[13]. Separate REDCap databases were created for each of the
participating regions and could be completed directly online
or transferred from paper copies.
Data collection
Regional data centres coordinated distribution to and com-
pletion of the survey by the sites. Clinical site investigators
affiliated with the IeDEA regional networks were primarily
responsible for completing the surveys. Data collection was
completed by January 2010. Sites in Southern Africa had
completed a comparable regional survey between January
and March 2009, and data from that survey were entered into
the IeDEA assessment tool, as appropriate. Additional data on
antiretroviral drug access from Southern Africa were collected
in April 2009. In the event that key data were missing from the
Southern African survey, their sites were asked to answer
additional questions during the analysis phase. All data were
entered and merged into the REDCap system before analysis.
Analysis
Site survey data were received from the five IeDEA regions
that had active paediatric HIV cohort databases: Asia, Central
Africa, East Africa, Southern Africa and West Africa. For the
purpose of analysis, only individual clinical sites that were
actively contributing individual patient data to their regional
paediatric cohort at the time of the assessment were
included.
Ten data categories were selected a priori for analysis,
including basic site characteristics, clinical service provision,
availability of laboratory services, prevention of mother-to-
child transmission (PMTCT) interventions, HIV diagnostic
testing, access to and use of antiretroviral drugs, management
of tuberculosis (TB), prophylaxis for Pneumocystis jiroveci
pneumonia, malaria management, and follow-up and transfer
practices. Categories were selected based on clinical and
programmatic relevance. Site-level responses were evaluated
for inconsistencies and sent to the IeDEA regional paediatric
representatives to coordinate an additional quality control
check, as needed. The corrected individual data summaries




Data were collected from all 63 sites contributing data on
64,762 children exposed to and/or living with HIV to the
IeDEA cohort for regional and multiregional analyses. This
included 10 clinics/sites in Asia, 4 in Central Africa, 29 in East
Africa, 10 in Southern Africa and 10 in West Africa (Table 1).
The majority were public government-run clinics (73%) in
urban settings (65%), providing care in combined adult
paediatric clinics (57%). Clinics received core programme
and clinical support funding through multiple sources,
including their own local governments (N51, 81%), re-
search grants (N36; 57%), the US PEPFAR programme
(N34, 54%), the Global Fund (N15, 24%) and patient
fees (N9, 14%). None of the sites required patients to pay
for first-line ART; two sites in West Africa required partial
payment for second-line ART.
The median upper age limit of children attending the clinic
ranged from 14 years at participating sites in East Africa to
18 years in Asia and Southern Africa. The median number of
half-day clinic sessions per week dedicated to children ranged
from one in East Africa to 10 in Southern African sites;
paediatric care provided during mixed adultpaediatric
clinics is not reflected in this response. Direct food assistance
was uncommon in Asia (30%) but available for malnourished
children in almost all East African sites (93%). Across the
regions, half of the sites had support groups for children, and
most offered disclosure counselling for caregivers (81%) and
children (71%).
After a missed clinic visit, sites utilized phone calls
(83%), home visits by clinic staff (21%) and home visits by
outreach workers (71%) to track patients and reschedule
appointments, when feasible. Loss to follow-up was defined
as 3 months of lost contact for 25 (40%) sites, 6 months
for 27 sites (43%) and 12 months for 6 sites (10%). The
reasons reported by sites for patient loss included non-
disclosure to family or neighbours (19%), death (35%) and
lack of financial resources within the family to sustain regular
care (44%).
Outside of East Africa, PMTCT programmes were less
commonly embedded into clinical care. Maternal antiretro-
viral regimens varied among sites and ranged from
single-dose nevirapine at delivery to triple-drug ART. Infant
care after delivery most commonly included post-natal
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antiretrovirals (79%), early infant diagnostic testing (79%)
and co-trimoxazole prophylaxis until infection status was
confirmed (81%). Sites reported their most commonly rec-
ommended infant feeding approaches, with 63% preferring
exclusive breastfeeding through to 46 months of age, and
21% preferring formula/replacement feeding at the time of
the survey.
Co-infection prophylaxis and management
PCP prophylaxis was not discontinued in children on therapy
at some sites within the African regions (e.g., 86% in East
Africa, 20% in West and Southern Africa), while all Asian sites
stopped co-trimoxazole after immunologic improvement on
ART. With regards to malaria, most (70%) African sites
reported that they used blood smears for diagnosis. Available
diagnostic testing for paediatric TB included skin testing
(33%), chest x-ray (89%), acid-fast bacilli smear (67%) and
culture (37%), as well as gastric washing (35%) and induced
sputum (21%) on-site. Most reported that TB treatment was
available (79%), with children at 60% of these sites being
offered directly observed therapy. Almost all sites reported
that isoniazid (92%), rifampicin (92%) and pyrazinamide
(89%) were standard drugs in first-line induction therapy
for TB in children, while 44% included ethambutol and 13%
included streptomycin as additional options. Although 71% of
sites reported using efavirenz in the initial ART regimens in
children older than three years of age during TB treatment,
79% used efavirenz or nevirapine.
Table 1. Programme characteristics of participating clinical centres*
Asia Central Africa East Africa Southern Africa West Africa
N10 N4 N29 N10 N10
Children under care, N 1416 475 29,772 30,864 2025
Public/government clinic 6 (60) 1 (25) 24 (83) 8 (80) 7 (70)
Clinic setting
- Urban 8 (80) 3 (75) 12 (41) 10 (100) 8 (80)
- Mixed urbanrural 2 (20) 0 14 (48) 0 1 (10)
Sources of funding
- Government 10 (100) 3 (75) 24 (83) 9 (90) 5 (50)
- Research grants 4 (40) 0 18 (62) 9 (90) 5 (50)
- US PEPFAR 0 0 25 (86) 7 (70) 2 (20)
- Global Fund 4 (40) 2 (50) 1 (3) 4 (40) 4 (40)
- Patient fees 1 (10) 2 (50) 1 (3) 2 (20) 3 (30)
Mixed adultpaediatric patient cohort 0 3 (75) 27 (93) 5 (50) 1 (10)
Upper age limit, median years (IQR) 18 (1518) 15 (14.815.5) 14 (1314) 18 (1618) 15 (1516)
Half-day dedicated paediatric clinic sessions,
median sessions (IQR)
1.5 (12.8) 2.5 (0.84.3) 1 (14) 10 (1010) 5 (3.55)
PMTCT embedded into clinical care at site 4 (40) 1 (25) 25 (86) 2 (20) 3 (30)
Most commonly recommended infant feeding
approach exclusive breastfeeding until 46
months
0 2 (50) 29 (100) 4 (40) 5 (50)
Food supplements for malnourished children 3 (30) 2 (50) 27 (93) 8 (80) 5 (50)
Presence of support group for children 6 (60) 2 (50) 12 (41) 8 (80) 3 (30)
Disclosure counselling available for caregivers 8 (80) 1 (25) 28 (97) 9 (90) 5 (50)
Disclosure counselling available for children 7 (70) 2 (50) 24 (83) 8 (80) 4 (40)
Interventions following missed visit
- Phone call 9 (90) 3 (75) 25 (86) 9 (90) 6 (60)
- Home visit by clinic staff 4 (40) 1 (25) 5 (17) 0 3 (30)
- Home visit by outreach worker 5 (50) 4 (100) 26 (90) 7 (70) 3 (30)
Definition of lost to follow-up: duration of
absence
- 3 months 0 2 (50) 10 (34) 7 (70) 6 (60)
- 6 months 3 (30) 2 (50) 19 (66) 1 (10) 2 (20)
- 12 months 5 (50) 0 0 0 1 (10)
IQR, interquartile range; PMTCT, prevention of mother-to-child HIV transmission programme.
*Data listed as N (%) unless otherwise specified.
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Antiretroviral drug access and monitoring
Sites reported having better access to stavudine-based (68%
with easy access) than to zidovudine-based (25% with easy
access) antiretroviral fixed-dose combinations for children.
Atazanavir was not available or not used in children in 98% of
African sites and 50% of Asian sites. There was no single
dominant method to assess paediatric treatment adherence,
with 40% of sites monitoring pill counts and 24% relying on
RNA viral load testing. Multiple interventions to support
adherence were utilized beyond counselling, including having
a pharmacist on the core clinical team (73%), routine reviews
of medication pick-up (67%) and pill boxes or blister packs
(48%).
HIV DNA PCR, CD4 and RNA PCR testing were widely
available across the regions, with reduced access to plasma
HIV-1 RNA viral load in Central and West Africa (Table 2). CD4
was regularly monitored in 95% of sites, with less frequent
monitoring of HIV-1 RNA (38%), creatinine (48%) and
cholesterol levels (35%). Asian and Southern African sites
had the highest overall levels of laboratory monitoring.
Discussion
The World Health Organization (WHO) and UNAIDS’ ‘‘Treat-
ment 2.0’’ is a global framework whose objective is to
achieve universal access for adults and children living with
HIV infection through simplified treatment with optimized
drug regimens, point-of-care diagnostics and decentralized
service delivery [14]. Given that a major challenge for
paediatric HIV care is to start all children under two years
of age on ART, a critical step in achieving these goals is
to better understand current programme resources and
operations at the country and regional level.
Paediatric IeDEA is a multicentre, international collabora-
tion of paediatric HIV treatment programmes in Asia and
Africa that forms an operational research network to describe
paediatric HIV care and treatment programmes, treatment
outcomes and their determinants. Characterizing intra- and
inter-country differences in current paediatric HIV care and
treatment management programmes can help to guide the
development of clinical practice guidelines, improve under-
standing of local resource availability and inform policy and
Table 2. Availability and utilization of diagnostic and monitoring testing*
Asia Central Africa East Africa Southern Africa West Africa
Test N10 N4 N29 N10 N10
HIV DNA PCR
- Available 9 (90) 3 (75) 29 (100) 10 (100) 5 (50)
- Turnaround time, median days (IQR) 14 (730) 30 (2260) 30 (1430) 9 (515) 14 (8.522)
CD4
- Available 10 (100) 4 (100) 29 (100) 10 (100) 9 (90)
- Regularly monitored 10 (100) 3 (75) 28 (97) 10 (100) 9 (90)
- Turnaround time, median days (IQR) 3 (26) 3.5 (2.54.3) 14 (2.814) 3 (27) 5 (35)
HIV RNA PCR
- Available 8 (80) 2 (50) 26 (90) 8 (80) 6 (60)
- Regularly monitored 9 (90) 2 (50) 1 (3) 7 (70) 5 (50)
- Turnaround time, median days (IQR) 10.5 (718) 21 and 30 days 30 (1430) 7 (512) 26 (1930)
ALT/AST
- Available 10 (100) 4 (100) 29 (100) 10 (100) 9 (90)
- Regularly monitored 10 (100) 2 (50) 24 (83) 7 (70) 9 (90)
Creatinine
- Available 10 (100) 4 (100) 29 (100) 10 (100) 9 (90)
- Regularly monitored 9 (90) 2 (50) 6 (21) 4 (40) 9 (90)
Total cholesterol
- Available 10 (100) 4 (100) 29 (100) 9 (90) 8 (80)
- Regularly monitored 8 (80) 2 (50) 0 7 (70) 5 (50)
Tuberculosis-related**
- Skin testing (e.g., purified protein derivative) 8 (80) 1 (25) 3 (10) 7 (70) 2 (20)
- Chest x-ray 10 (100) 3 (75) 28 (97) 9 (90) 6 (60)
- Acid-fast bacilli smear 10 (100) 3 (75) 14 (48) 10 (100) 5 (50)
- Acid-fast bacilli culture 8 (80) 1 (25) 3 (10) 8 (80) 3 (30)
- Drug susceptibility testing 7 (70) 0 0 9 (90) 2 (20)
IQR, interquartile range.
*Data listed as N (%) unless otherwise specified.
**Responses are not mutually exclusive.
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programmes by examining various models of care, clinical
outcomes and operational issues over time. However, on-
going changes inherent to progressive regional ART scale-up
and international prevention and treatment guidelines make
cross-regional comparisons over time even more challenging.
In addition, the sites participating in this survey were
predominantly in urban settings and the survey characterizes
resources reflecting the highest levels of HIV care and
treatment for children in these countries. Although they
may not necessarily be representative of the local HIV
programmes, many are national referral centres that provide
advice and direction for paediatric HIV care throughout the
different regions.
Although clinical resources and access to paediatric
antiretroviral formulations were generally high, there was
some variation between the regions. African and Asian sites
notably differed with regards to infant feeding recommenda-
tions. International guidelines promote the use of exclusive
breastfeeding due to higher levels of morbidity and mortality
in non-breastfed infants [15,16], but some Asian countries
continue to recommend exclusive formula feeding when
feasible and provide support for free formula (e.g. Thailand,
Vietnam, Malaysia, China) [17,18]. Some sites discontinued
cotrimoxazole prophylaxis after immune recovery, despite
the current WHO recommendations to continue it. With
regards to antiretroviral drug availability, African sites tended
to have easier access to tenofovir and abacavir than Asian
sites (data not shown), which may reflect the more frequent
eligibility for US PEPFAR pricing for drug procurement in sub-
Saharan Africa. Definitions of loss to follow-up were incon-
sistent, which may impact future reporting. In addition,
Central and West African sites tended to have less frequent
viral load monitoring.
Conclusions
To assess the long-term outcomes of ART in perinatally
infected children as they age into adolescence, national
paediatric HIV programmes in resource-constrained settings
will need to expand their focus beyond diagnosis and early
monitoring to a chronic disease model. More complex
laboratory monitoring and targeted sub-cohort studies of
toxicities and disease complications will also be needed
to understand the impact of HIV and its treatment on
adolescents and perinatally infected adults. Multiregional
platforms like IeDEA have the capacity to facilitate this more
advanced research agenda, promote data harmonization and
guide national programmes and inform global policy.
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Universitaire de Kamenge, Bujumbura Burundi; Dr. Marcel
Mbaya, Dr. Henri Mukumbi and Dr. Be´atrice Ilunga of Amo-
Congo, Democratic Republic of Congo; Dr. Marie-The´re`se
Abena Obama and Dr. Nelly Kamgaing of Centre Hospitalier
et Universitaire de Yaounde´, Yaounde´ Cameroon; Dr. Wilfred
Akam of Limbe´ Provincial Hospital, Limbe´, Cameroon;
IeDEA Central Africa Regional offices: Mr. Joseph Atibu,
Mr. Innocent Azinyue, Dr. Modeste Kiumbu, Mr. Christian
Konde´, Dr. John Ditekemena and Mr. Kashamuka
Mwandagalirwa; and RTI International: Dr. Jamie Newman
and Ms. Jennifer Hemingway-Foday.
The IeDEA East Africa Steering Group (20062011): We
acknowledge the contributions of the East African IeDEA sites
to this analysis and would like to thank Dr. Ayaya at the
United States Agency for International Development 
Academic Model Providing Access To Healthcare (USAID
AMPATH) Program, Eldoret, Kenya; Dr. Bukusi at Family
AIDS Care and Education Services (Faces), Kisumu, Kenya;
Dr. Lyamuya at Morogoro Regional Hospital, Tanzania;
Dr. Maruchu at Tumbi Regional Hospital, Tanzania; Dr. Otieno
at Nyanza Provincial Hospital, Kenya; Dr. Okong St. Francis
Nsambya Hospital, Kampala, Uganda; Dr. Deo Wabwire,
Makerere University, Kampala, Uganda; Dr. Masaba,
Mbale Regional Hospital, Uganda; Drs. Elul and Nuwagaba-
Biribonwoha at Columbia University’s Mailman School of
Public Health, USA and Dr. Cohen at University of California
San Francisco, USA; Mr. E. Sang, Ms. E. Rotich and Ms. M.
Achieng from the East African IeDEA Regional Data Center for
their contributions.
The IeDEA Southern Africa Steering Group: Member Sites:
*Cleophas Chimbetete, Newlands Clinic, Harare, Zimbabwe;
*Brian Eley, Red Cross Children’s Hospital, Cape Town,
South Africa; Christiane Fritz, SolidarMed Zimbabwe, Zim-
babwe; *Daniele Garone, Khayelitsha ART Programme and
Me´decins Sans Frontie`res, Cape Town, South Africa; *Janet
Giddy, McCord Hospital, Durban, South Africa; Christopher
Hoffmann, Aurum Institute for Health Research, South Africa;
Patrick MacPhail, Themba Lethu Clinic, Helen Joseph Hospital,
Johannesburg, South Africa; *Harry Moultrie, Wits Institute
for Sexual Reproductive Health, HIV & Related Diseases,
Faculty of Health Sciences, University of the Witwatersrand,
Johannesburg, and Harriet Shezi Children’s Clinic, Chris Hani
Baragwanath Hospital, Soweto, South Africa; James Ndirangu,
Hlabisa HIV Treatment and Care Programme, South Africa;
Sabrina Pestilli, SolidarMed Mozambique, Mozambique;
*Sam Phiri, Lighthouse Clinic, Lilongwe, Malawi; *Hans
Prozesky and Helena Rabie, Tygerberg Academic Hospital,
Stellenbosch, South Africa; Jeff Stringer, Center for Infectious
Disease Research in Zambia, Zambia; *Karl Technau,
Empilweni Service and Research Unit, Rahima Moosa Mother
and Child Hospital, University of the Witwatersrand, Johan-
nesburg, South Africa; *Paula Vaz, Paediatric Day Hospital,
Maputo, Mozambique; *Robin Wood, Gugulethu and
Masiphumelele ART Programmes and Desmond Tutu HIV
Centre, Cape Town, South Africa. Central Team: Matthias
Egger, Claire Graber, Fritz Kaeser, Olivia Keiser, Institute of
Social and Preventive Medicine, University of Bern, Bern,
Switzerland; Andrew Boulle, Morna Cornell, Mary-Ann
Davies, Nicola Maxwell, School of Public Health and Family
Medicine, University of Cape Town, Cape Town, South Africa.
*Sites that contributed data to this analysis.
The IeDEA West Africa Working Group: Primary Investiga-
tors: Pr Franc¸ois Dabis* (Inserm, U897, ISPED, University
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Bordeaux Segalen, Bordeaux, France), Pr Emmanuel Bissag-
nene* (SMIT, CHU de Treichville, Abidjan, Coˆte d’Ivoire).
Clinical Investigators by country and alphabetical order
(*Member of the IeDEA West Africa Technical Committee):
Jocelyn Akakpo, Alain Azonde´kon, Jules Bashi, Sagbo Gratien,
Sikiratou Koumakpaı¨, Marcel D. Zannou* (Benin); Ye Diarra,
Eric-Arnaud Diendere, Joseph Drabo*, Fla Koueta (Burkina
Faso); Edmond Aka-Addi, Clarisse Amani-Bosse, Franck-
Olivier Ba-Gomis, Franc¸ois Eboua-Tanoh, Serge-Paul Eholie*,
Calixte Guehi, Kouakou Kouadio, Serge-Olivier Koule´, Euge`ne
Messou, Albert Minga, Aristophane Tanon, Marguerite
Timite´-Konan, Pety Toure´, (Coˆte d’Ivoire); Kevin Peterson*
(Gambia); Bamenla Goka, Lorna Renner* (Ghana); Hadizatou
Coulibaly, Fatoumata Dicko, Moussa Maiga*, Daouda Minta,
Mariam Sylla, Hamar Alassane Traore´; Man Charurat* (Man
Charurat); Bernard Diop, Fatou Ly Ndiaye, Papa Salif Sow,
Haby Signate´ Sy*, Judicae¨l Tine (Senegal). Epidemiology and
Statistical Unit (Inserm, U897, ISPED, Universite´ Bordeaux
Segalen, Bordeaux, France): Eric Balestre, Didier K. Ekoue´vi*,
Antoine Jaquet*, Vale´riane Leroy*, Charlotte Lewden*, Karen
Malateste, Annie Sasco, Rodolphe Thiebaut. Data Manage-
ment Unit (PACCI, CHU Treichville, Abidjan, Coˆte d’Ivoire):
Ge´rard Allou, Jean Claude Azani, Patrick Coffie. Paediatric
clinical centres by city and country: Abidjan, Coˆte d’Ivoire:
ACONDA-CEPREF, ACONDA-MTCT-Plus, CHU de Yopougon,
Centre Inte´gre´ de Recherche Bioclinique d’Abidjan (CIRBA).
Accra, Ghana: Korle Bu Teaching Hospital, Bamako. Mali:
Hoˆpital Gabriel Toure´. Cotonou. Benin: Centre National
Hospitalo-Universitaire Hubert Maga, Hoˆpital d’Instruction
des Arme´es. Dakar, Senegal: Hoˆpital d’Enfants Albert-Royer.
Fajara, Gambia: Medical Research Council. Ouagadougou,
Burkina-Faso: Centre Hospitalier Charles de Gaulle. Adminis-
tration: Alexandra Doring and Elodie Rabourdin (ISPED),
Hughes Dje´touan, Bertin Kouadio and Adrienne Kouakou
(PACCI).
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